- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05791331
Дыхательная механика для доставки индивидуального экзогенного сурфактанта (REMEDIES)
Рандомизированное контролируемое исследование колебательной механики в сравнении с критериями на основе оксигенации для терапии сурфактантом
This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:
- to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
- to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.
Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.
Study Arms:
A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).
Обзор исследования
Статус
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Anna Lavizzari, MD
- Номер телефона: 0039 3208715095
- Электронная почта: anna.lavizzari@gmail.com
Места учебы
-
-
-
Milan, Италия
- Рекрутинг
- Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
-
Контакт:
- Anna Lavizzari, MD
- Номер телефона: 0039 3208715095
- Электронная почта: anna.lavizzari@gmail.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Gestational age (GA) ≥ 27+0 and < 33+0 weeks
- Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
- Inborn
- Written parental consent obtained
- Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care
Exclusion Criteria:
- Major congenital anomalies
- Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
- Surfactant therapy prior to the study entry
- Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
- Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
- Any clinical condition which may place the infants at undue risk as deemed by clinicians
- Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
- Outborn patients
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: A/Control
Surfactant administration following clinical assessment |
Surfactant is administered following oxygenation-based criteria |
|
Экспериментальный: B/Intervention
Surfactant administration following both lung mechanics assessment and clinical assessment |
Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Days of respiratory support
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of required respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
First surfactant administration
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Time of first surfactant administration (in hours) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of non-invasive respiratory support
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of non-invasive respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of invasive respiratory support
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of invasive respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Patients intubated and mechanically ventilated
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of patients intubated and mechanically ventilated |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Patients receiving multiple surfactant doses
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of patients receiving multiple surfactant doses |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days on supplemental oxygen
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days on supplemental oxygen |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Total cumulative oxygen exposure
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Total cumulative oxygen exposure computed as the time integral of the FiO2 values |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants receiving more than 28 days of respiratory support
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants receiving more than 28 days of respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing BPD
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing BPD according to the definition by NICHD 2016 |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing air-leaks
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing air-leaks |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing prematurity-associated complications
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants discharged home with oxygen or respiratory support
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants discharged home with oxygen or respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days to achieve full-enteral feeding
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of hospitalization
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of hospitalization |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants receiving postnatal steroids
Временное ограничение: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants receiving postnatal steroids |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- Sperimentazione 3115
- Studio Numero 6379 (Другой идентификатор: Comitato Etico Milano Area 2)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .